Apr 21, 20211 min
$MRNA -3% Supply agreement with Israel for 2022. source
$SRNE -1% Announces ph 1 results of COVI-MSC in ICU Covid-19 patients. source
$ALKS +1% New exploratory analysis from ph 3 study presented. source
$EVLO -5% Updates ph 1 data presented. source
$YMAB +3% update on Type B meeting with FDA, maintain timeline of Q2/Q3 for BLA resubmission. source
$CRBP +2% Ph 2 enrollment completed, results expected H2 2021. source
$BLUE -1% Withdraws Zynteglo from German market after pricing negotiations, LentiGlobin SAE determined to be transfusion-dependent anemia not MDS. source
$SNDX -28% Presents updates ph 1/2 data from AUGMENT-101 study. Ph 2 to initiated by end of quarter. source
$CYCN +7% Will host pipeline update and KOL call on 4/27/21. source
$SEEL +2% Positive EMA opinion on Orphan Drug Designation for SLS-005 for ALS. source
$GWPH -1% EU approval of Epidyolex for TSC. source
$KALV +3% Ph 2 study put on clinical hold by FDA, requiring more information and analysis from preclinical studies. No new studies requested. source
$ERYP +1% Requested pre-BLA meeting for eryapase fo hypersensitive ALL patients, with BLA submission expected H2 2021. source
$LCTX 0% WW licensing and dev agreement with Immunomic for novel product candidate. source